Vetter expands its footprint in Asia Pacific 'sweet spot'

The pharmaceutical service provider will be better positioned to support local and global customers, helping them to meet stringent development, manufacturing and packaging requirements of their injectable drugs.

Vetter has officially opened a new branch office in South Korea. The new office in Songdo is located within the biologics cluster, which is often referred to as a ‘sweet spot’ by the industry as it houses numerous prominent biopharmaceutical companies and service providers.

Vetter expands its footprint in Asia Pacific 'sweet spot'
Another ribbon cutting ceremony takes place for Vetter in the Asia Pacific region.

Strengthening its global footprint in the Asia Pacific (APAC) region has been an ongoing goal for Vetter. The company established its APAC hub in Singapore in 2014, and subsequently formed a Japanese subsidiary by opening an office in Tokyo in 2015. Although the pharmaceutical service provider had already been active in the South Korean market for years, the establishment of its own local branch office underlines the company’s commitment to the Asia Pacific market, particularly South Korea. With the new footprint, Vetter will be better positioned to support its existing South Korean business as well as that of new local and global customers, helping them to meet stringent development, manufacturing and packaging requirements of their injectable drugs.

“Today is yet another milestone for our company. This new office will allow us to directly serve both local and global companies with South Korean market interests,” said Vetter Managing Director Peter Soelkner. “We are certain that our market presence and activities in this market will serve as an additional base and contribution for Vetter’s future global organic growth.”

Read More


Categories

Market News

Other news in “Market News”

Automating the process of screening excipients for solubilising drug candidates

Automating the process of screening excipients for solubilising drug candidates 

8 Nov 2017
Poor aggregation will see ADC targets fail or face long delays

Poor aggregation will see ADC targets fail or face long delays 

15 Nov 2017
Copley Scientific introduces new, upgraded breath simulators for inhaled product testing

Copley Scientific introduces new, upgraded breath simulators for inhaled product testing 

14 Nov 2017